Claims from 192,793 newly diagnosed dry eye disease patients showed prescription initiation in 12.4%, indicating substantial ...
Mortality rates for DTR Gram-negative infections remain unchanged despite the increased availability and use of newer antimicrobial agents.
Q4 2025 Earnings Call April 15, 2026 5:00 PM EDTCompany ParticipantsBradford Amman - CFO, Treasurer & SecretaryR.
Those residing in low food access areas have higher comorbidity score and more complications, higher incidence of reoperation.
A 1000 mg ×2 induction regimen followed by maintenance every 6–12 months was associated with near-elimination of relapse ...
The EndoArt artificial endothelial layer showed positive results across multiple studies presented by specialists at the ...
With new data and treatment strategies discussed at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual ...
The aim of the new guideline is to expand on current cardiovascular guidelines to include evidence from the neurologic and ...
Shayla Talei, 31, documents her life with multiple debilitating chronic illness for over 249,000 followers on TikTok ...
Immunomodulatory therapies in patients with congenital ichthyosis are associated with a reduced risk for contact dermatitis ...
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva,” the “Company” “we” or “us”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the ...
The FDA has granted Fast Track designation to KT-621, a first-in-class oral STAT6 degrader for moderate to severe eosinophilic asthma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results